Novartis Spinoff Sandoz to Start Trading as Standalone Drugmaker
- Swiss company could offer above-industry growth, analysts say
- Split leaves Novartis focused solely on innovative treatments
This article is for subscribers only.
Sandoz Group AG, the maker of copycat medicines, was spun off from drugmaker Novartis AG to begin life as a standalone company on Wednesday when its shares started trading on Switzerland’s stock exchange.
Sandoz opened at 24 Swiss francs, giving it a market capitalization of nearly 11 billion Swiss francs ($12 billion) in early trading.